The new bid surpasses an offer SK Capital and Carlyle Group made last month for the gene therapy developer, which Bluebird’s ...

I believe Blue Bird shares could be near rock bottom, with potential support in the low $30s after a steep 40% selloff.

(Reuters) -Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.

Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right ...

A rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio. | A rival bidder has emerged to ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

US gene therapy company bluebird bio (Nasdaq: BLUE) has confirmed receipt of an unsolicited non-binding written proposal from ...

Donald Campbell's Bluebird has had a new jet engine installed as part of efforts to run the record-breaking craft in the Lake ...

Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...

Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right ...